Objective: To investigate how antibodies against anti-tumour necrosis factor (anti-TNF) agents influence response after switching from infliximab to adalimumab in rheumatoid arthritis (RA).
Methods: This cohort study consisted of 235 patients with RA, all treated with adalimumab. At baseline 52 patients (22%) had been previously treated with infliximab ('switchers'), and 183 (78%) were anti-TNF naive. Disease activity (using the 28-joint count Disease Activity Score (DAS28)) and presence of antibodies against infliximab and adalimumab were assessed. Clinical response to adalimumab was compared between switchers and anti-TNF naive patients and their anti-infliximab and anti-adalimumab antibody status.
Results: After 28 weeks of adalimumab treatment the decrease in DAS28 (Delta DAS28) for the 235 patients was 1.6+/-1.5 (mean+/-SD). Anti-adalimumab antibodies were detected in 46 patients (20%). Delta DAS28 was 1.8+/-1.4 in patients without anti-adalimumab and 0.6+/-1.3 in patients with anti-adalimumab (p<0.0001). Thirty-three of the 52 switchers (63%) had anti-infliximab antibodies. Patients with anti-infliximab more often developed anti-adalimumab than anti-TNF naive patients (11 (33%) vs 32 (18%); p=0.039). Delta DAS28 was greater for anti-TNF naive patients (1.7+/-1.5) than for switchers without anti-infliximab antibodies (Delta DAS28=0.9+/-1.4) (p=0.009). Delta DAS28 for switchers with anti-infliximab was 1.2+/-1.3 and did not differ significantly from anti-TNF naive patients (p=0.262).
Conclusion: Switchers with anti-infliximab antibodies more often develop antibodies against adalimumab than anti-TNF naive patients. Response to adalimumab was limited in switchers without anti-infliximab antibodies, which raises the question whether a second anti-TNF treatment should be offered to patients with RA for whom an initial treatment with an anti-TNF blocker fails, in the absence of anti-biological antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ard.2009.112847 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Observational Study to Compare Biological Drug Concentration Quantification Techniques and Immunogenicity in Patients with Immune-Mediated Diseases.
Biomedicines
April 2024
Department of Pharmacy, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña (UDC), 15006 A Coruña, Spain.
Article Synopsis
- Measuring trough concentrations of biological drugs and anti-drug antibodies is important for optimizing treatments, with ELISA being the traditional method used.
- A study compared drug levels and antibody concentrations using a new chemiluminescence technique (i-TRACK) to the established ELISA method (TRITURUS) for drugs like infliximab, adalimumab, vedolizumab, and ustekinumab.
- While both methods showed excellent correlation for measuring drug concentrations, the chemiluminescent technique generally reported lower values, and further research is needed for ustekinumab and vedolizumab due to modest results.
Detection of infliximab, adalimumab, and anti-drug antibodies: Development and validation of new monotest, automated assays on multiparametric instrument.
Pract Lab Med
March 2024
DIESSE Diagnostica Senese S.p.A. Società Benefit: Strada dei Laghi 35-39, Monteriggioni, Siena, Italy.
Article Synopsis
- The study aimed to automate immunoassays for measuring serum levels of infliximab and adalimumab along with anti-drug antibodies using the CHORUS Promonitor kits.
- By comparing the automated kits against the manual versions, researchers analyzed sensitivity and specificity while running tests using human serum samples and drug additions on the CHORUS TRIO instrument.
- Results showed that the automated kits were highly accurate and consistent, demonstrating strong agreement with manual kits and confirming their potential for use in clinical settings for monitoring patients treated with these drugs.
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Aliment Pharmacol Ther
October 2022
Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
Article Synopsis
- Anti-drug antibodies linked to treatment failure in inflammatory bowel disease (IBD) patients on anti-TNF agents were analyzed in a large UK study involving 1058 participants.
- The study found that patients who developed antibodies to their first anti-TNF drug were more likely to also develop antibodies to their second anti-TNF drug, indicating a potential pattern of immunogenicity across different treatments.
- Introducing an immunomodulator when switching anti-TNF therapies boosted treatment persistence in patients with immunogenicity, suggesting that combined therapies may enhance outcomes in IBD management.
Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease.
J Crohns Colitis
February 2022
Exeter Inflammatory Bowel Disease and Pharmacogenetics Group, University of Exeter, Exeter, UK.
Article Synopsis
- The COVID-19 pandemic prompted a shift to telemedicine for patients with chronic inflammatory disorders, highlighting a need for innovative methods of remote therapeutic drug monitoring, such as low-volume intracapillary blood sampling done at home.* -
- A study comparing patient-led intracapillary sampling (fingerpricks) to traditional venepuncture found that the new method was equivalent in measuring drug levels and was well-accepted by patients, with 69% preferring it over traditional methods.* -
- During the first UK lockdown, requests for therapeutic drug monitoring of adalimumab decreased significantly, while those for infliximab remained stable; over 75% of patients successfully returned two blood samples within 14 days for analysis
Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
J Pharm Biomed Anal
May 2021
Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain; Instituto de Investigación Sanitaria de La Princesa, Madrid, Spain; Biomedical Research Network Centre for Liver and Digestive Diseases (CIBEREHD), Madrid, Spain. Electronic address:
Article Synopsis
- - The study evaluates a fast method called Quantum Blue (QB) for detecting anti-drug antibodies (ADA) against two common biological drugs, Adalimumab (ADL) and infliximab (IFX), comparing it to traditional ELISA kits (Promonitor and Lisa-Tracker).
- - Results showed that QB performed similarly to ELISA for anti-ADL antibodies, but struggled with anti-IFX detection, revealing significant discrepancies and low agreement rates, which could affect clinical decisions.
- - The findings suggest that while QB is a reliable option for ADL monitoring, improvements are necessary for its use with IFX to ensure accurate monitoring in patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!